ACIP review of the hepatitis B birth dose vaccination remains a grave concern - Please read more here.

Site Search

You searched for "hepatitis D"

  • What Are You Doing for World Hepatitis Day?

      What Are You Doing For World Hepatitis Day? Every July 28, we celebrate World Hepatitis Day in honor of Dr. Baruch Blumberg’s birthday. Dr. Blumberg discovered the hepatitis B virus in 1967 and subsequently developed the hepatitis B vaccine two years later in 1969. We commemorate World Hepatitis Day by raising awareness about viral hepatitis. With almost 300 million individuals living with hepatitis B worldwide, it is so important to bring awareness to this preventable and treatable disease to create meaningful change. This year, the World Hepatitis Alliance’s theme is Hepatitis Can’t Wait.  Their campaign highlights how we cannot wait to get tested, vaccinated, reduce stigma and discrimination, and we can’t wait to act. You can join their campaign here. The Hepatitis B Foundation is dedicated to raising the profile of hepatitis B as an urgent public health problem, improving the quality of life for those living with hepatitis B and working towards eliminating hepatitis B related stigma and discrimination. This year we are elevating the voice of individuals living with hepatitis B by highlighting five new #BtheVoice videos from real people living in Nigeria. These audio recordings were captured by Catherine Freeland, MPH, Associate Director of Public Health at the Hepatitis B Foundation during a recent trip to Nigeria where she worked on enhancing and the need for timely birth dose to prevent mother to child transmission of hepatitis B. We believe that elevating the voices of those who have hepatitis B is the best way to spread awareness for the need to find a cure, provide screening and treatment and work to fight stigma and discrimination. You can watch the videos here. So, what will you do today to honor World Hepatitis Day? It can be as simple as sharing hepatitis B related information on Facebook, Instagram, Twitter, WeChat, or WhatsApp. You could tell your friends and family about hepatitis B and how it impacts your life or people in your

    http://www.hepb.org/blog/world-hepatitis-day-2022/
  • I Have Hepatitis B. Could I Also Be Infected with Hepatitis D?

    By Sierra Pellechio, Hepatitis Delta Connect Coordinator Hepatitis delta, or hepatitis D, is an aggressive form of hepatitis that can only infect someone who is also infected with hepatitis B. People can become infected with hepatitis B and hepatitis D from the same exposure, or people who are already infected with hepatitis B can later be infected with hepatitis D. Coinfection can promote more rapid progression to cirrhosis and liver cancer than being infected with hepatitis B alone and will require an altered treatment and management plan. Being aware could save your life! Hepatitis D can be spread similarly to hepatitis B, through exposure to blood or bodily fluids of an infected person. People with hepatitis B are likely to develop a chronic hepatitis delta coinfection if they are exposed to the virus, making it important for you and your doctor to be aware of the signs of a coinfection. Cues to suspect a coinfection: You have chronic hepatitis B but are not responding to antiviral treatment, or you have signs of liver damage even though your viral load is low (HBV DNA below 2,000 IU/mL) Note: Fatty liver disease (caused by obesity) and liver damage from alcohol or environmental toxins should be ruled out as causes of liver damage before testing for hepatitis D. It is also important for hepatitis B patients who originate from Sub-Saharan Africa, China, Russia, the Middle East, Mongolia, Romania, Georgia, Turkey, Pakistan and the Amazonian River Basin to be tested for hepatitis D, where it is more common. Most of the time, patients do not have any signs or symptoms to let them know they are coinfected, so a simple blood test is the only way to know for sure! Talk to your liver specialist about testing at your next appointment. Hepatitis Delta Connect is a dedicated program of the Hepatitis B Foundation aimed to provide information and support for those affected by hepatitis D. Please visit our website, www.hepdconnect.org for more information and follow us on

    http://www.hepb.org/blog/hepatitis-b-also-infected-hepatitis-delta/
  • Diagnosing Hepatitis D in the U.S.

    Robert Gish, MD David Hillyard, MD By Sierra Pellechio, Hepatitis Delta Connect Coordinator Hepatitis D, or hepatitis delta, is the most severe form of viral hepatitis known to humans. The hepatitis D virus infects the liver and is dependent on the hepatitis B virus to reproduce. This means that people who are already infected with hepatitis B are at risk of contracting hepatitis D as well. Worldwide, more than 257 million people live with hepatitis B and of this number, an estimated 15-20 million are also infected with the hepatitis delta virus (HDV). While uncommon in the United States, HDV co-infection is more common in parts of the world such as China, Russia, Middle East, Mongolia, Romania, Georgia, Turkey, Pakistan, Africa, and the Amazonian river basin. For this reason, it is important to test hepatitis B patients who originate from these higher endemic areas for hepatitis D. Anyone with chronic hepatitis B who is not responding to antiviral treatment, or who has signs of liver damage even though they have a low viral load (HBV DNA below 2,000 IU/mL) should also be tested. Fatty liver disease (caused by obesity) and liver damage from alcohol or environmental toxins should be ruled out as causes of liver damage before testing for HDV.  Hepatitis D infections lead to more serious liver disease than hepatitis B infection alone. It is associated with faster progression to liver fibrosis, increased risk of liver cancer, and early decompensated cirrhosis and liver failure. This is why it is so important that people with hepatitis B and D coinfection are diagnosed before it can lead to severe complications. Robert Gish, MD, Hepatitis B Foundation Medical Director, and David Hillyard, MD, Medical Director, Molecular Infectious Diseases, ARUP Laboratories, tackled the topic of diagnosing hepatitis D in a webinar in October. Dr. Gish also answered additional questions, which are featured below: What is the first step in diagnosing an HDV patient? The HDV

    http://www.hepb.org/blog/diagnosing-hepatitis-delta-u-s/
  • A Capitol Celebration: US Leaders in Hepatitis B Celebrate World Hepatitis Day

    Hep B United (HBU), a coalition established by the Hepatitis B Foundation (HBF) and the Association of Asian Pacific Community Health Organizations (AAPCHO), held its fifth annual Hep B United Summit from July 26th to 28th in Washington D.C. The summit was held to promote screening and prevention strategies and advocate for a cure to further HBU’s mission to eliminate hepatitis B in the United States. The summit is the largest gathering of hepatitis B leaders from around the country including public health agencies, national non-profit organizations, community coalitions, and individuals and family members affected by hep B. Catherine Freeland, MPH, Public Health Manager of HBF, said, “The summit is like a family reunion.” It’s an opportunity for HBU members to convene, share best strategies, and celebrate their wins over the past five years. The partnerships within HBU ensures that best practices and resources are shared as well. "Once we have a cure, we are committed to making sure chronically infected Americans get it," Chari Cohen, DrPH, MPH, co-chair of HBU mentioned during the summit. Over the past year, HBU screened 22,556, educated 52,194, and reached over 6 million people with in-language hepatitis B messaging! That’s a win for sure! As a part of the summit, HBU partners visited Capitol Hill to discuss with federal legislators the need to support hepatitis B and liver cancer research, education, screening, and treatment programs. A Congressional reception was also held to highlight the “#justB: Real People Sharing their Stories of Hepatitis B” storytelling campaign, which increases awareness of hepatitis B through personal stories. There were also meeting sessions focusing on capacity building, sustaining local hepatitis B coalitions, and best ways to utilize resources like the “Know Hepatitis B” campaign from the CDC and Hep B United and the #justB campaign. The Hep B United Summit is a way to celebrate World Hepatitis Day, which is

    http://www.hepb.org/blog/capitol-celebration-us-leaders-hepatitis-b-celebrate-world-hepatitis-day/
  • The Medical Community Wakes Up to a Dangerous Threat to People with Hepatitis B – Coinfection with Hepatitis D

    By Christine Kukka In the U.S. and around the world, the medical community is finally acknowledging a hidden threat to people with hepatitis B – a virulent liver coinfection that requires the presence of the hepatitis B surface antigen (HBsAg) to survive. Hepatitis D (Delta), which causes the most severe liver infection known to humans, infects between 15 to 20 million people worldwide and an estimated 20,000 people living with chronic hepatitis B in the U.S. For years, health officials assumed hepatitis D did not threaten Americans and occurred primarily in Central Asia and Sub-Saharan Africa. However, recent U.S. Centers for Disease Control and Prevention (CDC) studies found 4 to 5 percent of Americans with chronic hepatitis B are also infected with hepatitis D. As a result of these findings, researchers including Hepatitis B Foundation's Medical Director Dr. Robert Gish, are now pushing medical organizations to establish hepatitis D testing and monitoring guidelines so doctors will start testing patients for this dangerous liver disease. Recently, the foundation sponsored a webinar, attended by dozens of healthcare providers, patients and officials from around the world, in which Dr. Gish outlined whom should be tested for hepatitis D, and how it should be treated. A new webinar that examines hepatitis D prevalence in the U.S. is scheduled for 3 p.m. (EST), Wednesday, June 28. To register for the webinar click here. How do people get infected with hepatitis D? Infection occurs when people are exposed to blood and body fluids from someone with an active hepatitis D infection. Basically, they get both hepatitis B and D in one exposure. This is called an acute coinfection. Some healthy adults are able to clear both infections, but they often experience serious liver damage during the clearance or recovery phase. Another way to become infected is if someone infected with chronic hepatitis B is exposed to someone with hepatitis D. This is called a

    http://www.hepb.org/blog/medical-community-wakes-dangerous-threat-people-hepatitis-b-coinfection-hepatitis-d/
  • B the Change Advocacy Challenge

    Please join us and B The Change during our week of action leading up to and including World Hepatitis Day. By joining our Advocacy Challenge, you will bring needed attention to hepatitis B and the challenges faced by those with hep B.  You can participate and be entered for a chance to win a $50 gift card!  *Submit this form no later than Thursday, July 29th to confirm your participation in the advocacy challenge and be eligible for the gift card drawing. Six winners will be selected and notified by HBF staff the week of August 2nd. If you have any questions, please email us at advocate@hepb.org. Below is a list of steps you can take to B The Change: 1. If you were not able to attend our kick-off call, you can watch the video here.  2. Sign Up for the B The Change Action Center here.  3. Share the B The Change Action Center on your social media. Use the hashtags #HepBUnite and #BTheChange and tag us at @hepbfoundation and @hepbunited.  4. Register for the Universal Hepatitis B Screening Webinar.  5. Pledge to help advance universal adult hepatitis B vaccination (U.S. only).  6. Post a photo from a previous World Hepatitis Day event you participated in. Use the hashtags #HepUnite and #BTheChange and tag us at @hepbfoundation and @hepbunited. 7. Create a post using the B Informed Social Media Toolkit. Use the hashtags #HepBUnite and #BTheChange and tag us at @hepbfoundation and @hepbunited. 8. Share hepatitis B policy priorities with your members of Congress. Take action here (U.S. only).  9. What's YOUR reason to B The Change? Let us know! Help us spread the word by commenting on our social media posts that ask this question on Wednesday, July 28th. Comments help to increase our reach so that more people see our posts and we can get the word out about hep b.   Thank you for being an advocate and caring about the nearly 300 million people living with hepatitis B today. Congratulations on being the change! In addition to your amazing acts of advocacy, please consider making a donation to our Find Your Why for World Hepatitis Day fundraiser. Your donation will help fund the life-changing work that is made possible at the Hepatitis B Foundation and Blumberg Institute. Please donate here.    UPDATE: For World Hepatitis Day this year, we received over 100 entries into our B the Change Advocacy Challenge – a virtual week of action led by the Hepatitis B Foundation and Hep B United. Advocates from around the world participated by attending the Week of Action Kick-off Call, signing up for the B the Change Action Center and sharing it with their networks, posting hepatitis B information and resources on social media using the B Informed Social Media Toolkit, and supporting other World Hepatitis Day campaigns online. Dozens of advocates in the U.S. pledged to show their support for universal adult hepatitis B vaccination and emailed Members of Congress to educate them about key hepatitis B stats and policy priorities. Overall, the B the Change Advocacy Challenge generated more than 26,000 social media impressions. Thank you to everyone who participated, and congratulations to the six gift card winners from Bulgaria, Cameroon, South Sudan, and the United States.  

    https://www.hepb.org/news-and-events/b-the-change-advocacy-challenge/
  • Awards

    Hepatitis B Foundation Award History *Denotes deceased honoree Blumberg Prize (Established in 2012) 2022 - Stephan Urban, PhD - Heidelberg University Hospital (hepatitis delta) Watch his presentation here.  2021 – Wenhui Li, PhD - National Institute of Biological Sciences, Beijing, China (HBV) 2020 – John Taylor, PhD – Fox Chase Cancer Center (hepatitis delta) 2019 – Christoph Seeger, PhD – Fox Chase Cancer Center (HBV) 2018 – *Prof DS Chen, MD – Academia Sinica (Taiwan’s National Academy)  (HBV) 2017 – Mario Rizetto, PhD – Italy (hepatitis delta) 2016 – *Bud Tennant, PhD – Cornell U. (HBV)  2015 – Eugene Schiff, MD – U. Miami (HBV clinician) 2014 – *Thomas Starzl , MD, PhD – U. Pittsburgh (1st liver transplantation) 2013 – Robert Purcell, PhD – NIH (HAV, HBV) 2012 (Inaugural) – Howard Koh, MD – Assistant Sec. of Health at HHS (HBV advocate) 2011 – 20th Anniversary with Tribute to Dr. Baruch S. Blumberg (he passed April 2011) 2010 – *R. Palmer Beasley, MD – Baylor U., TX (HBV and HCC link) 2009 – Brian McMahon, MD – Alaska/CDC (HBV clinician and AASLD Guidelines) 2008 – Anna Lok, MD – U. Michigan (HBV clinician and AASLD Guidelines 2007 - Francis V. Chisari, MD, The Scripps Research Institute2006 - Raymond F. Schinazi, PhD, Emory University 2003 - Jay Hoofnagle, MD, National Institutes of Health 2000 - Harvey J. Alter, MD, National Institutes of Health 1999 - William S. Mason, PhD, Fox Chase Cancer Center            Jesse Summers, PhD, University of New Mexico             Hie-Won Hann, MD, Thomas Jefferson University 1998 - *W. Thomas London, MD, Fox Chase Cancer Center 1997 - Raymond Dwek, D. Phil, FRS, University of Oxford Community Commitment Award (Inaugurated in 2011) 2022 - Su Wang, MD, PhD 2021 - Rev. Jason Crum Escalera 2020 – Susana Guigere, Esq. 2019 – Paula Wong 2018 – Fred Beans 2017 - Marvin and Dee Ann Woodall 2016 – Renold Capocasale 2015 – Bruce and Cynthia Maryanoff 2014 – Jim and Teri Holton 2013 – Debbie Wagner 2012 – Bridget Wingert 2011 – Brad Segall Distinguished Leadership Award 2000 - Deborah Wexler, MD, Immunization Action Coalition 1998 - *Joshua Feldstein, PhD, Delaware Valley College 1997 - Harvey Rich, CPA, Rich, Gelwarg, Lampf Associates 1997 - Nat Brown, MD, GlaxoWellcome Founders’ Award 2005 – *Bill Stephenson, PhD, Vice-Provost for Research, Drexel U.  2004 – PA Governor Mark Schweiker 2002 – Bill & Melinda Gates Foundation (accepted by Mark Kane, MD, MPH) 2001 – *Baruch S. Blumberg, MD, PhD, Nobel Prize Winner 2000 - Timothy M. Block, PhD, Jefferson Medical College 1999 – Paul and Janine Witte, Originetics 1998 - Connelly Foundation – Mrs. Josephine C. Mandeville, President                                                Lewis Bluemle, MD, Vice-President 1997 - Joseph S. Gonnella, MD, Jefferson Medical College Distinguished Public Service Award 2000 - *Pa. State Senator Richard A. Tilghman 1999 - Pa. State Senator Joe Conti 1998 - *U.S. Senator Arlen Specter 1997 - U.S. Congressman James Greenwood   Special Commendation 1999 - Mr. Alan Brownstein, President, American Liver Foundation   Bruce Witte Lecture (Established by Paul and Janine Witte in 2000) 2020 – Marion Peters, MD (U California, San Fran) 2019 – John C. Martin, PhD (Retired CEO, Gilead) 2018 - Dennis Liotta, PhD (Emory U, Georgia) 2017 – James Ou, MD, PhD (Keck School of Medicine, U Southern California) 2016 - Antonio Bertolleti, MD (Duke-National University of Singapore) 2015 - Hashem El Serag, MD, MPH (Baylor College of Medicine, Texas) 2014 - Charles Rice, PhD (Rockefeller U., New York) 2013 - Jorge Marrero, MD (UT Southwestern, Texas) 2012 - Snorri S.Thorgeirsson, MD, PhD (NCI/NIH, Wash DC) 2011 – Adrian DiBisceglie, MD (St. Louis Med U, Missouri) 2010 - T. Jake Liang, MD  (NIDDK/NIH, Wash DC) 2009 - Stephen Locarnini, MD, PhD (Victorian Infectious Diseases Reference Laboratory, Australia) 2008 - Rafi Ahmed, PhD (Emory U, Georgia) 2007 - Stanley M. Lemon, MD (U of Texas Medical Branch) 2006 - John M. Taylor, PhD (Fox Chase Cancer Center, Phila) 2005 - *T.S. Benedict Yen, MD, PhD (U of California, San Fran) 2004 - *Emmet Keeffe, MD (U of California, San Fran) 2003 – None 2002 – Frank Chisari, MD (Scripps Research Institute, California) 2001 – *John Gerin, PhD (Georgetown U, Wash DC) 2000 – Raymond Schinazi, PhD (Emory U, Atlanta) – Inaugural Speaker

    https://www.hepb.org/news-and-events/awards-and-events/awards/
  • Hepatitis B Foundation Calls for Universal Screening for Hepatitis B

    All Americans should know their status to eliminate public health threat DOYLESTOWN, PA (July 25, 2018) In recognition of World Hepatitis Day on July 28, the Hepatitis B Foundation (HBF) is calling for all Americans to be tested for hepatitis B infection. The formal recommendation was approved by HBF’s Scientific and Medical Advisory Board to achieve the World Health Organization’s (WHO) ambitious goal of eliminating hepatitis B by the year 2030. Up to 2.2 million Americans, and more than 292 million people worldwide, are chronically infected with this serious liver disease virus, which can lead to cirrhosis and liver cancer. Because there are often few symptoms, hepatitis B frequently goes undiagnosed, with experts estimating that only 20-30% are aware of their infection. “We are making the recommendation to test all adults for hepatitis B because we believe it is the only way to identify those who need care and reduce deaths due to hepatitis B infection,” explains Timothy Block, PhD, President of the Hepatitis B Foundation and its Baruch S. Blumberg Institute.  “Current guidelines recommend testing for people in high risk populations, but data suggests that up to 40% of those infected may not fall within those populations. It is imperative that we test everyone in order to provide care and education that will reduce deaths from hepatitis B.” This recommendation is a bold shift from the current hepatitis B risk-based screening guidelines published by the Centers for Disease Control and Prevention (CDC) and the U.S. Preventive Services Task Force (USPSTF). But multiple challenges, including the complexity of risk-based screening, and stigma surrounding hepatitis B, have led to a lack of adherence of the current guidelines, and there has not been a significant increase in hepatitis B testing in the U.S. HBF’s recommendation is limited to adults, because universal infant vaccination has been standard in the U.S. since 1991. The new recommendation includes the provision that individuals who test negative for hepatitis B in the screening and have not been vaccinated, be offered and receive an effective hepatitis B vaccine. The WHO has called for reduction in the number of deaths due to hepatitis B by at least 65% by the year 2030. While increased vaccination rates can reduce the number of new cases, “the only way to achieve the WHO goal is to identify those with a chronic infection, by screening, and then linking them with care,” says Chari Cohen, DrPH, MPH, Vice President for Public Health and Programs, at the Hepatitis B Foundation. “Testing based only on risk factors has failed to identify over a million infected individuals. It is time to move forward with universal testing to make this effort most effective and most efficient.” While there is still no cure for chronic hepatitis B, current medications work by lowering the amount of virus in the blood, which in turn reduces damage to the liver. Effective treatment has been shown to reduce death from liver disease by 50-70% in those with chronic infection. In addition, there are many drugs currently in development that could provide even more effective treatment or a cure in the future. However, it is estimated that fewer than 7% of Americans with chronic hepatitis B are currently receiving treatment. “It is absolutely within our power to reduce deaths due to hepatitis B,” says Robert Gish, MD, HBF Medical Director. “But it will only be possible if we identify everyone who needs treatment and help them find care they can afford.” About Hepatitis B: Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus that attacks and injures the liver. Each year up to 1 million people die from hepatitis B worldwide despite the fact that it is preventable and treatable. Hepatitis B is a “silent epidemic” because most people do not have symptoms when they are newly infected or chronically infected. Thus, they can unknowingly spread the virus to others and continue the silent spread of hepatitis B. For people who are chronically infected but don’t have any symptoms, their liver is still being silently damaged which can develop into serious liver disease such as cirrhosis or liver cancer. About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at facebook.com/hepbfoundation or call 215-489-4900.   # # #  

    https://www.hepb.org/news-and-events/news-2/hepatitis-b-foundation-calls-for-universal-screening-for-hepatitis-b/
  • Printable Fact Sheets (English)

    Fact Sheet for Patients (Short) Fact Sheet for Patients (Long) Fact Sheet for Providers                              Hep Delta Facts Infographic  Hep D Fast Facts Hepatitis Delta Clinical Trials Fact Sheet (Updated July 2022)

    https://www.hepb.org/research-and-programs/hepdeltaconnect/resources/printable-fact-sheets-english/
  • Hepatitis B Foundation Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection

    Collaboration with Eiger Biopharma and ARUP Laboratories Focuses on Deadly Form of Viral Hepatitis DOYLESTOWN, PA October 2016, The Hepatitis B Foundation today announced the launch of a nationwide hepatitis delta virus (HDV) campaign to expand patient access to testing and raise awareness of HDV, an infection that occurs only in patients with hepatitis B. The goal of the campaign is to educate healthcare professionals and people with hepatitis B about the risk of hepatitis delta while reducing barriers to testing. Achieving this goal will result in patients knowing their HDV status. This week, the Foundation launched a comprehensive HDV educational website (www.hepdconnect.org). The Foundation is collaborating with Eiger BioPharmaceuticals, a biopharmaceutical company focused on targeted therapies for rare diseases, and ARUP Laboratories, Inc., a national clinical and anatomic pathology reference laboratory, on this initiative. “There is a tremendous lack of awareness among patients and providers about the serious problem of HDV co-infection, due in-part to limited access to tests and the lack of therapies approved to treat HDV,” said Timothy Block, PhD, President and co-founder of the Hepatitis B Foundation.“Given recent advances in the availability of HDV viral load testing and an expanding pipeline of anti-HDV drug candidates, now is the time to launch an outreach campaign such as this. By increasing provider and patient awareness about HDV and the importance of testing for HDV to reduce the burden of disease, we will be able to make significant advances in eliminating the lethal HDV coinfection among hepatitis B patients.” Hepatitis delta (or Hepatitis D) is caused by infection with HDV and is considered to be one of the most severe forms of viral hepatitis in humans. Hepatitis delta occurs only as a co-infection in individuals already infected with hepatitis B. Hepatitis delta leads to more severe liver disease than hepatitis B alone and is associated with accelerated liver fibrosis, liver cancer, liver failure, and higher risk of death and liver transplants. “Eiger is committed to playing a leading role in developing novel treatments for HDV infection, the most lethal form of hepatitis, and building awareness of the need for widespread testing,” said Eduardo Martins, MD, DPhil, Senior Vice President of Liver and Infectious Diseases Drug Development at Eiger.  “The campaign represents an important step toward expanding and accelerating broad-scale HDV testing, and arming physicians and patients with information they need.” Hepatitis delta is a disease with a significant impact on global health, and due to migration, may affect up to approximately 15-20 million people worldwide. The prevalence of HDV varies among different parts of the world. Globally, HDV infection is reported to be present in approximately 5-6% of chronic hepatitis B patients. The prevalence of HDV in patients infected with chronic hepatitis B is even higher in certain regions, including certain parts of Mongolia, China, Russia, Central Asia, Pakistan, Turkey, Africa, Pacific Islands and South America, with an HDV prevalence as high as 60% being reported in hepatitis B-infected patients in Mongolia and Pakistan. About the Hepatitis B Foundation The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read the blog at hepb.org/blog, follow the Hepatitis B Foundation on Twitter @HepBFoundation and on Facebook at www.facebook.com/hepbfoundation or call 215-489-4900. About Eiger BioPharmaceuticals, Inc. Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed. About ARUP Laboratories, Inc.Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation’s top university teaching hospitals and children’s hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®.  

    https://www.hepb.org/news-and-events/news-2/delta-connect-release/